Impact of Perioperative Multimodal Blood Management of Bone Tumors of Hip on Early Postoperative Functional Recovery: A Retrospective Cohort Study

Why It Matters

Accelerating early functional recovery can reduce hospital stay, lower rehabilitation costs, and improve quality of life for orthopedic oncology patients. The study provides evidence that targeted blood‑management can offset pre‑operative anemia risks.

Key Takeaways

• Multimodal protocol improved fatigue scores at one month.
• Harris Hip Scores rose to 30.6 vs 25.3 in multimodal group.
• Early functional gains achieved despite lower baseline hemoglobin.
• Erythropoietin and iron supplementation supported restrictive transfusion strategy.
• Recovery advantage disappeared by three months postoperatively.

Pulse Analysis

Managing peri‑operative blood loss is a persistent challenge in orthopedic oncology, where extensive resections and high vascularity often lead to anemia and delayed mobilization. Traditional approaches rely on liberal transfusion thresholds, which can increase infection risk and lengthen hospital stays. Recent advances, such as pre‑operative erythropoietin stimulation and intravenous iron, aim to boost endogenous red‑cell production while limiting allogeneic blood exposure. When combined with restrictive transfusion protocols, these strategies create a multimodal framework that addresses both the supply and demand sides of peri‑operative hemoglobin management.

The recent retrospective cohort of 38 hip bone tumor surgeries demonstrates that this multimodal approach can translate into measurable early functional benefits. Patients receiving erythropoietin, iron, and tighter transfusion criteria reported a 5.8‑point improvement in FACIT‑Fatigue scores and a 30.6‑point rise in Harris Hip Scores at one month, outperforming controls despite lower baseline hemoglobin and longer operations. These metrics indicate faster pain reduction, better energy levels, and more rapid return to weight‑bearing activities—critical factors for postoperative quality of life and for initiating adjuvant therapies on schedule.

Beyond the immediate clinical gains, the protocol offers broader economic and strategic implications. Shortened rehabilitation timelines can lower inpatient costs, reduce the need for intensive physiotherapy, and free surgical capacity for additional cases. Moreover, minimizing transfusion exposure aligns with patient‑safety initiatives and antimicrobial stewardship goals. As hospitals seek value‑based care models, integrating multimodal blood‑management into orthopedic oncology pathways could become a standard of care, prompting further prospective trials to refine dosing regimens and identify patient subgroups that benefit most.